LNTH
Lantheus Holdings, Inc.
NASDAQ · Healthcare · Drug Manufacturers - Specialty & Generic · US
$100.55
−0.25%Year over year
Reported trailing growth
- Revenue
- +2.3%
- EBITDA
- +1.8%
- EBIT
- -30.9%
- EPS
- +7.1%
- Free cash flow
- +8.3%
- Operating cash flow
- +2.4%
Forward estimates
Based on analyst estimates
- Revenue
- -1.2%
- EBITDA
- +15.0%
- EPS
- +33.8%
Three-year CAGR
- Revenue
- +18.1%
- EBITDA
- +70.2%
- EBIT
- +104.8%
- Net income
- +102.6%
- EPS
- +103.6%
- Free cash flow
- +10.4%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026